Previous 10 | Next 10 |
Friday's midday action saw its share of bright spots despite weakness in the overall markets. Gainers included Centene (NYSE:CNC), which climbed in the wake of takeover speculation. Meanwhile, ForgeRock (NYSE:FORG) continued its post-IPO advance, building on gains posted in its debut ses...
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCell...
BeiGene’s European commercial team is preparing to launch BRUKINSA, the company’s first medicine submitted for marketing authorization in the EU, upon approval The CHMP recommendation is based on results from the Phase 3 ASPEN trial, in which BRUKINSA demonstrate...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! There’s only one day of trading left so let’s start it off right with a look at the biggest pre-market stock movers for Friday. Source: ventdusud / Shutterstock.com We’re s...
Leap Therapeutics (NASDAQ:LPTX) soars 47.1% premarket after announcing updated positive data from from the first-line cohort of Phase 2a DisTinGuish study, evaluating DKN-01 in combination with BeiGene's (NASDAQ:BGNE) tislelizumab, and chemotherapy, in patients with gastri...
It's scary to invest in stocks from China these days, considering what's going on in the country. Government crackdowns, cancellations of IPOs, and increased regulations are all reasons for alarm. Recently, government authorities took aim at ride-hailing apps for using unqualified drivers a...
This marks the third FDA approval for BRUKINSA and first approval in marginal zone lymphoma Twenty percent of patients achieved complete remission with single-agent BRUKINSA BRUKINSA was generally well-tolerated, consistent with its known safety profile Bei...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For September
France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO. Sinovac Biotech reported that a third dose of its inac...
This marks the first ex-China regulatory filing for tislelizumab, following approval in five indications in China The accepted BLA, filed in collaboration with Novartis, is supported by the positive global Phase 3 RATIONALE 302 trial in patients with previously treated, advanc...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...